Quest Diagnostics SVP & general counsel sells $5.5m in shares

Quest Diagnostics' Senior Vice President and General Counsel, Michael E. Prevoznik, sold 22,677 shares of the company's common stock for approximately $5.51 million on August 28, 2026. The sale, which was executed under a pre-arranged Rule 10b5-1 trading plan, took place in multiple transactions at prices ranging from $242.270 to $245.247 per share, near the stock's 52-week high.

Prior to the sale, Prevoznik had acquired the same number of shares by exercising non-qualified stock options, which had vested over three annual periods. Despite these transactions, Prevoznik still holds a total of 36,557 shares of Quest Diagnostics common stock, both directly and indirectly. Quest Diagnostics recently reported strong second-quarter earnings, surpassing Wall Street expectations with an adjusted earnings per share of $3.12 and revenue of $3.04 billion.

The company has also raised its full-year outlook, and Truist Securities raised its price target for the stock to $250.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.